{"id":46006,"date":"2022-01-17T07:53:29","date_gmt":"2022-01-17T12:53:29","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=46006"},"modified":"2022-01-16T07:55:52","modified_gmt":"2022-01-16T12:55:52","slug":"pfizer-inks-a-research-collaboration-with-beam-therapeutics","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006","title":{"rendered":"Pfizer Inks A Research Collaboration with Beam Therapeutics"},"content":{"rendered":"

Pfizer (<\/span>PFE<\/b>) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (<\/span>BEAM<\/b>). The two are joining forces to advance the development of novel in-vivo base editing programs. PFE shares rose 0.93% to close at $56.24 on January 10.<\/span><\/p>\n

Pfizer is a company that develops, manufactures, and distributes healthcare products, including medicine and vaccines. It specializes in areas of oncology, inflammation vaccines, and rare diseases.<\/span><\/p>\n

Pfizer’s earnings report\u00a0for Q4 2021 is scheduled for February 08, 2022. PFE dividends have increased over the past 12 months. The dividend yield currently stands at 2.81%.<\/span><\/p>\n

Pfizer-Beam Partnership<\/b><\/p>\n

The base editing program will leverage Beam\u2019s proprietary in vivo technologies to address genetic diseases that target the liver, muscle, and central nervous system. Merging the technologies with Pfizer\u2019s proven experience in should lead to transformative therapies.<\/span><\/p>\n

Under the terms of the agreement, Beam is tasked with conducting all research activities on three undisclosed targets. On the other hand, Pfizer may opt for exclusive licenses to each development candidate. It will also be responsible for all development activities.<\/span><\/p>\n

Beam is also mandated to receive $300 million in an upfront payment. Should Pfizer opt-in license rights on all the three targets under development, Beam would be eligible to milestone payments to a tune of $1.35 billion. Beam is also entitled to receive royalties on global net sales on each licensed program.<\/span><\/p>\n

Beam – Acuitas Agreement<\/b><\/p>\n

In addition, Pfizer has entered into a development and option agreement with Acuitas Therapeutic. The partnership paves the way for the company to gain access to valuable lipid nanoparticle formulation technology for use in mRNA vaccines and therapeutics. The company also gains access to license Acuitas LNP technology for up to 10 targets.<\/span><\/p>\n

Stock rating<\/b><\/p>\n

Last week, Bank of America Securities analyst Geoff Meacham upgraded Pfizer stock to a Buy from a Hold and increased the price target to $70 from $59 implying 24.47% upside potential to current levels. According to the analyst, The roll out of a oral COVID-19 therapy in 2022 should lead to more durable revenues and robust cash flow for Pfizer.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Pfizer (PFE) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (BEAM). The two are joining forces to advance the development of novel […]<\/p>\n","protected":false},"author":15,"featured_media":46007,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[993,207,15819,15820,15027],"stock_ticker":[],"class_list":["post-46006","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysepfe","tag-pfe","tag-pfe-news","tag-pfe-stock","tag-pfizer-nysepfe","entry"],"acf":[],"yoast_head":"\nPfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Pfizer (PFE) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (BEAM). The two are joining forces to advance the development of novel […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-17T12:53:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1880\" \/>\n\t<meta property=\"og:image:height\" content=\"1253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Pfizer Inks A Research Collaboration with Beam Therapeutics\",\"datePublished\":\"2022-01-17T12:53:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\"},\"wordCount\":340,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg\",\"keywords\":[\"NYSE:PFE\",\"PFE\",\"PFE News\",\"PFE Stock\",\"Pfizer (NYSE:PFE)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\",\"name\":\"Pfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg\",\"datePublished\":\"2022-01-17T12:53:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg\",\"width\":1880,\"height\":1253},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Inks A Research Collaboration with Beam Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006","og_locale":"en_US","og_type":"article","og_title":"Pfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR","og_description":"Pfizer (PFE) has inked four-year research collaboration agreement with biotechnology company Beam Therapeutics (BEAM). The two are joining forces to advance the development of novel […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2022-01-17T12:53:29+00:00","og_image":[{"width":1880,"height":1253,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Pfizer Inks A Research Collaboration with Beam Therapeutics","datePublished":"2022-01-17T12:53:29+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006"},"wordCount":340,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg","keywords":["NYSE:PFE","PFE","PFE News","PFE Stock","Pfizer (NYSE:PFE)"],"articleSection":["Health"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006","name":"Pfizer Inks A Research Collaboration with Beam Therapeutics - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg","datePublished":"2022-01-17T12:53:29+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/01\/Pfizer.jpeg","width":1880,"height":1253},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inks-a-research-collaboration-with-beam-therapeutics-46006#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Inks A Research Collaboration with Beam Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/46006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=46006"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/46006\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/46007"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=46006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=46006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=46006"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=46006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}